Cargando…

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion

PURPOSE: To assess treatment interval extension after switching from ranibizumab to aflibercept intravitreal injections in macular edema (ME) due to central retinal vein occlusion (CRVO) with an insufficient response or frequent recurrences to initial treatment. METHODS: CRVO eyes treated with ranib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nghiem-Buffet, Sylvia, Glacet-Bernard, Agnès, Addou-Regnard, Manar, Souied, Eric H., Cohen, Salomon Y., Giocanti-Auregan, Audrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079418/ https://www.ncbi.nlm.nih.gov/pubmed/30116635 http://dx.doi.org/10.1155/2018/8656495

Ejemplares similares

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema
por: Sarda, Valérie, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
por: Best, Anne-Laurence, et al.
Publicado: (2018)

Docetaxel Retinopathy: A Case Report
por: Nghiem-Buffet, Sylvia, et al.
Publicado: (2017)

Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
por: Korobelnik, Jean-François, et al.
Publicado: (2022)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
por: Tagami, Mizuki, et al.
Publicado: (2017)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum]
Publicado: (2017)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Bayat, Alper Halil, et al.
Publicado: (2019)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective
por: Adedokun, Lola, et al.
Publicado: (2016)

Multimodal Imaging of Unilateral Acute Maculopathy Associated with Hand, Foot, and Mouth Disease: A Case Series
por: Anjou, Mickael, et al.
Publicado: (2022)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice
por: Giocanti-Auregan, Audrey, et al.
Publicado: (2016)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose, Remya, et al.
Publicado: (2016)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Management of macular edema due to central retinal vein occlusion – The role of aflibercept
por: Rhoades, William, et al.
Publicado: (2017)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study
por: Akbas, Yusuf Berk, et al.
Publicado: (2023)

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study
por: Huang, Yu-Te, et al.
Publicado: (2022)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
por: Hykin, Philip, et al.
Publicado: (2019)

Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
por: Souied, Eric H., et al.
Publicado: (2016)

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion
por: Chhablani, Jay
Publicado: (2015)

Aflibercept in macular edema secondary to retinal vein occlusion: A real life study
por: Ozkaya, Abdullah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vgsi0fgg53eufer27qlt2tmis7